Literature DB >> 19535994

Brains with medial temporal lobe neurofibrillary tangles but no neuritic amyloid plaques are a diagnostic dilemma but may have pathogenetic aspects distinct from Alzheimer disease.

Peter T Nelson1, Erin L Abner, Frederick A Schmitt, Richard J Kryscio, Gregory A Jicha, Karen Santacruz, Charles D Smith, Ela Patel, William R Markesbery.   

Abstract

Brains that have many neurofibrillary tangles (NFTs) in medial temporal lobe structures (Braak stage III or IV) but no cortical neuritic plaques (NPs) may be a diagnostic dilemma; they also raise questions about the amyloid cascade hypothesis of Alzheimer disease (AD) in which NFT development is thought to occur downstream of the development of amyloid plaques. To determine the clinical, demographic, and biological factors related to NFT+/NP- cases, we analyzed 26 NFT+/NP- patient brains identified from the University of Kentucky AD Center autopsy cohort (n=502); most of these patients were at least 85 years old and lacked profound antemortem cognitive impairment. A subset of the cases had NFTs in the medulla oblongata. Aberrant trans-activator regulatory DNA-binding protein 43 immunohistochemical staining was seen in 5 of the 26 cases with the clinical diagnoses of AD or mild cognitive impairment. We also queried cases in the National Alzheimer's Coordinating Center Registry (n=5,108) and found 219 NFT+/NP- cases. Those patients had a relatively high likelihood of belonging to a birth cohort with the highest incidence of influenza infection during the 1918 to 1919 pandemic. This observation may link the pathogenesis in NFT+/NP- cases to encephalitis during childhood. We conclude that NFT+/NP- cases comprise approximately 5% of aged individuals in multiple data sets; these cases are not necessarily within the spectrum of AD.

Entities:  

Mesh:

Year:  2009        PMID: 19535994      PMCID: PMC2725359          DOI: 10.1097/NEN.0b013e3181aacbe9

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  65 in total

1.  Children and encephalitis lethargica: a historical review.

Authors:  Joel A Vilensky; Paul Foley; Sid Gilman
Journal:  Pediatr Neurol       Date:  2007-08       Impact factor: 3.372

2.  Quantitative analysis of neurofibrillary pathology in a general population to reappraise neuropathological criteria for senile dementia of the neurofibrillary tangle type (tangle-only dementia): the Hisayama Study.

Authors:  Kazuhito Noda; Kensuke Sasaki; Kohei Fujimi; Yoshinobu Wakisaka; Yumihiro Tanizaki; Yoshiyuki Wakugawa; Yutaka Kiyohara; Mitsuo Iida; Hisamiti Aizawa; Toru Iwaki
Journal:  Neuropathology       Date:  2006-12       Impact factor: 1.906

Review 3.  Progress from Alzheimer's tangles to pathological tau points towards more effective therapies now.

Authors:  Virginia M-Y Lee; John Q Trojanowski
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472

4.  Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Manuela Neumann; Deepak M Sampathu; Linda K Kwong; Adam C Truax; Matthew C Micsenyi; Thomas T Chou; Jennifer Bruce; Theresa Schuck; Murray Grossman; Christopher M Clark; Leo F McCluskey; Bruce L Miller; Eliezer Masliah; Ian R Mackenzie; Howard Feldman; Wolfgang Feiden; Hans A Kretzschmar; John Q Trojanowski; Virginia M-Y Lee
Journal:  Science       Date:  2006-10-06       Impact factor: 47.728

Review 5.  Tauopathies: classification and clinical update on neurodegenerative diseases associated with microtubule-associated protein tau.

Authors:  D R Williams
Journal:  Intern Med J       Date:  2006-10       Impact factor: 2.048

6.  TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis.

Authors:  Tetsuaki Arai; Masato Hasegawa; Haruhiko Akiyama; Kenji Ikeda; Takashi Nonaka; Hiroshi Mori; David Mann; Kuniaki Tsuchiya; Mari Yoshida; Yoshio Hashizume; Tatsuro Oda
Journal:  Biochem Biophys Res Commun       Date:  2006-10-30       Impact factor: 3.575

7.  Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies.

Authors:  Mari Yoshida
Journal:  Neuropathology       Date:  2006-10       Impact factor: 1.906

8.  Neurofibrillary tangle-predominant dementia: comparison with classical Alzheimer disease.

Authors:  K A Jellinger; J Attems
Journal:  Acta Neuropathol       Date:  2006-11-07       Impact factor: 17.088

Review 9.  RNA in brain disease: no longer just "the messenger in the middle".

Authors:  Peter T Nelson; Jeffrey N Keller
Journal:  J Neuropathol Exp Neurol       Date:  2007-06       Impact factor: 3.685

Review 10.  A century of Alzheimer's disease.

Authors:  Michel Goedert; Maria Grazia Spillantini
Journal:  Science       Date:  2006-11-03       Impact factor: 47.728

View more
  59 in total

1.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach.

Authors:  Thomas J Montine; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; John Q Trojanowski; Harry V Vinters; Bradley T Hyman
Journal:  Acta Neuropathol       Date:  2011-11-20       Impact factor: 17.088

2.  National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease.

Authors:  Bradley T Hyman; Creighton H Phelps; Thomas G Beach; Eileen H Bigio; Nigel J Cairns; Maria C Carrillo; Dennis W Dickson; Charles Duyckaerts; Matthew P Frosch; Eliezer Masliah; Suzanne S Mirra; Peter T Nelson; Julie A Schneider; Dietmar Rudolf Thal; Bill Thies; John Q Trojanowski; Harry V Vinters; Thomas J Montine
Journal:  Alzheimers Dement       Date:  2012-01       Impact factor: 21.566

3.  Correlation of brain amyloid with "aerobic glycolysis": A question of assumptions?

Authors:  Michael E Phelps; Jorge R Barrio
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

4.  Association of APOE with tau-tangle pathology with and without β-amyloid.

Authors:  Jose M Farfel; Lei Yu; Philip L De Jager; Julie A Schneider; David A Bennett
Journal:  Neurobiol Aging       Date:  2015-09-28       Impact factor: 4.673

5.  Neuropathological associates of multiple cognitive functions in two community-based cohorts of older adults.

Authors:  N Maritza Dowling; Sarah Tomaszewski Farias; Bruce R Reed; Joshua A Sonnen; Milton E Strauss; Julie A Schneider; David A Bennett; Dan Mungas
Journal:  J Int Neuropsychol Soc       Date:  2011-07       Impact factor: 2.892

Review 6.  Alzheimer's disease is not "brain aging": neuropathological, genetic, and epidemiological human studies.

Authors:  Peter T Nelson; Elizabeth Head; Frederick A Schmitt; Paulina R Davis; Janna H Neltner; Gregory A Jicha; Erin L Abner; Charles D Smith; Linda J Van Eldik; Richard J Kryscio; Stephen W Scheff
Journal:  Acta Neuropathol       Date:  2011-04-24       Impact factor: 17.088

7.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study.

Authors:  Melissa E Murray; Neill R Graff-Radford; Owen A Ross; Ronald C Petersen; Ranjan Duara; Dennis W Dickson
Journal:  Lancet Neurol       Date:  2011-07-27       Impact factor: 44.182

8.  MicroRNA in Situ Hybridization in the Human Entorhinal and Transentorhinal Cortex.

Authors:  Peter T Nelson; James Dimayuga; Bernard R Wilfred
Journal:  Front Hum Neurosci       Date:  2010-02-22       Impact factor: 3.169

Review 9.  Primary Age-Related Tauopathy (PART): Addressing the Spectrum of Neuronal Tauopathic Changes in the Aging Brain.

Authors:  Richard A Hickman; Xena E Flowers; Thomas Wisniewski
Journal:  Curr Neurol Neurosci Rep       Date:  2020-07-14       Impact factor: 5.081

Review 10.  Challenges of multimorbidity of the aging brain: a critical update.

Authors:  Kurt A Jellinger; Johannes Attems
Journal:  J Neural Transm (Vienna)       Date:  2014-08-05       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.